News
03-17-2011, 06:30 AM
CytRx Corporation, a biopharmaceutical company specializing in oncology, today announced that it has initiated an open-label Phase 1b safety and dose escalation clinical trial with INNO-206 at the Sarcoma Oncology Center in Santa Monica, California. The clinical trial will include up to 24 patients with advanced solid tumors who have failed standard therapies.
More... (http://www.news-medical.net/news/20110317/CytRx-commences-INNO-206-Phase-1b-trial-in-advanced-solid-tumors.aspx)
More... (http://www.news-medical.net/news/20110317/CytRx-commences-INNO-206-Phase-1b-trial-in-advanced-solid-tumors.aspx)